NOVO Nordisk, the drugmaker behind the hit obesity treatment Wegovy, signed research deals with a pair of biotechs backed by Flagship Pioneering, agreeing to pay as much as US$1.1 billion to develop new technologies to tackle diseases linked to weight.
